Fremanezumab Reduces Prolonged Sporadic Hemiplegic Migraine Rate
Fremanezumab, a CGRP-targeting preventive therapy, may reduce prolonged sporadic hemiplegic migraine attacks, offering a promising option for patients with stroke-like symptoms and limited disease-specific treatments.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.